SCHEMBL243496

SCHEMBL243496

CSCCC(C)(N)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 1/20 0.52
ARG1 P05089 1/20 0.47
ARG2 P78540 1/20 0.47
NOS2 P35228 5/20 0.41
NOS1 P29475 3/20 0.41
NOS3 P29474 1/20 0.41
BLM P54132 2/20 0.37
RNPEP Q9H4A4 1/20 0.34
ALDH1A1 P00352 4/20 0.34
MEN1 O00255 2/20 0.34
CYP1A2 P05177 2/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
EGFR P00533 1/20 0.34
FYN P06241 1/20 0.34
POLB P06746 1/20 0.34
CYP3A4 P08684 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162368 1.00 GGT1 (0.52) GGT1ARG1ARG2NOS2NOS1
SCHEMBL5614525 1.00 GGT1 (0.52) GGT1ARG1ARG2NOS2NOS1
SCHEMBL162014 1.00 GGT1 (0.52) GGT1ARG1ARG2NOS2NOS1
SCHEMBL5614536 1.00 GGT1 (0.52) GGT1ARG1ARG2NOS2NOS1
Hydrochloric Acid SCHEMBL13585526 0.98 GGT1 (0.50) GGT1ARG1ARG2NOS2NOS1
SCHEMBL4263059 0.90 GGT1 (0.44) GGT1ARG1ARG2NOS2NOS1
SCHEMBL29054949 0.89 GGT1 (0.43) GGT1ARG1ARG2NOS2NOS1
SCHEMBL2720103 0.89 ARG1 (0.47) GGT1ARG1ARG2NOS2NOS1
SCHEMBL11192504 0.82 NOS1 (0.33) GGT1ARG1ARG2NOS2NOS1
SCHEMBL8687592 0.80 GGT1 (0.65) GGT1ARG1ARG2NOS2NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 781 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110914425-B High Throughput (HTP) genome engineering platform for improving spinosyns 齐默尔根公司 2024-06-25 CN claimed
CN-116670151-A Antibacterial cyclic peptides targeting acinetobacter and other gram negative pathogens 犹他大学研究基金会 2023-08-29 CN claimed
US-20230111252-A1 THIOSEMICARBAZATES AND USES THEREOF THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2023-04-13 US claimed
US-20200115705-A1 A HIGH-THROUGHPUT (HTP) GENOMIC ENGINEERING PLATFORM FOR IMPROVING SACCHAROPOLYSPORA SPINOSA ZYMERGEN INC. (US) 2020-04-16 US claimed
EP-3635110-A2 A HIGH-THROUGHPUT (HTP) GENOMIC ENGINEERING PLATFORM FOR IMPROVING SACCHAROPOLYSPORA SPINOSA Zymergen, Inc. (US) 2020-04-15 EP claimed
CN-110914425-A High Throughput (HTP) genome engineering platform for improving saccharopolyspora spinosa 齐默尔根公司 2020-03-24 CN claimed
CN-109477840-A For non-destructively determining the method and system of Fowl Sex in ovum 因欧沃私人有限责任公司 2019-03-15 CN claimed
WO-2018226893-A2 A HIGH-THROUGHPUT (HTP) GENOMIC ENGINEERING PLATFORM FOR IMPROVING SACCHAROPOLYSPORA SPINOSA ZYMERGEN INC. (US) 2018-12-13 WO claimed
EP-1591520-B1 Microorganism producing L-threonine having inactivated tyR gene, method of producing the same and method of producing L-threonine using the microorganism CJ CHEILJEDANG CORP (KR) 2017-11-29 EP claimed
US-20160318987-A1 PROTEASE RESISTANT PEPTIDES MEDIMMUNE LIMITED (GB) 2016-11-03 US claimed
WO-2004045539-A2 ANTI-MICROBIAL AGENTS DERIVED FROM METHIONINE SULFOXIMINE ANALOGUES REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2004-06-03 WO claimed
EP-1017358-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-07-12 EP claimed
US-5939458-A APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN GILLETTE COMPANY, THE 1999-08-17 US claimed
US-5925551-A MUTANT ASPERGILLUS TERREUS STRAIN; FOR HIGH PRODUCTION OF MEVINOLINIC ACID, A CHEMICAL INTERMEDIATE OF LOVASTATIN; BY-PRODUCT INHIBITION; USING MONOSACCHARIDES LIKE GLUCOSE AND GALACTOSE AS CARBON SOURCE DURING FERMENTATION CHONG KUN DANG CORPORATION (KR) 1999-07-20 US claimed
WO-1999015136-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-04-01 WO claimed
CN-1036832-C Composition containing a penem or carbapenem artibiotic and the use of the same SANKYO CO (JP) 1997-12-31 CN claimed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP claimed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US claimed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP claimed
CN-86107574-A Compositions containing penem or carbapenem antibiotics and their use 1987-05-20 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230111252-A1 THIOSEMICARBAZATES AND USES THEREOF TST, ABAT, AADAC GGT1 628/4885ARG1 2587/4885ARG2 1813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.